Northwestern Mutual Wealth Management Co. Acquires 211,222 Shares of Alto Neuroscience, Inc. $ANRO

Northwestern Mutual Wealth Management Co. grew its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 14,567.0% in the 4th quarter, Holdings Channel reports. The fund owned 212,672 shares of the company’s stock after buying an additional 211,222 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Alto Neuroscience were worth $3,786,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ANRO. Invesco Ltd. bought a new position in shares of Alto Neuroscience in the first quarter worth about $67,000. AQR Capital Management LLC bought a new position in shares of Alto Neuroscience in the first quarter worth about $52,000. Marshall Wace LLP lifted its holdings in shares of Alto Neuroscience by 9.9% in the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after acquiring an additional 84,417 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Alto Neuroscience in the second quarter worth about $240,000. Finally, Bridgeway Capital Management LLC lifted its holdings in shares of Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after acquiring an additional 25,000 shares during the last quarter.

Alto Neuroscience Price Performance

Alto Neuroscience stock opened at $21.22 on Monday. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $744.57 million, a PE ratio of -8.77 and a beta of 1.62. Alto Neuroscience, Inc. has a 12 month low of $2.15 and a 12 month high of $28.44. The stock has a 50-day moving average price of $23.21 and a two-hundred day moving average price of $18.80.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). Analysts expect that Alto Neuroscience, Inc. will post -2.98 EPS for the current year.

Analyst Ratings Changes

ANRO has been the subject of a number of research reports. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 target price on shares of Alto Neuroscience in a report on Monday, March 16th. BTIG Research increased their target price on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Alto Neuroscience in a report on Monday, May 11th. Robert W. Baird dropped their target price on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Finally, Weiss Ratings upgraded Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.